High Infiltration of CD203c Mast Cells Reflects Immunosuppression and Hinders Prognostic Benefit in Stage II-III Colorectal Cancer

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2023 Feb 28

PMID 36852299

Authors

Jing Li

Yuzhen Mo

Qingqing Wei

Jian Chen

Guozeng Xu

Affiliations

Soon will be listed here.

Abstract

Background: Activated mast cells (AMCs) have been fully researched in inflammation and allergic reactions. However, the protumoral role of AMCs and their biomarker CD203c has not yet been investigated in colorectal cancer (CRC).

Methods: We retrospectively collected 449 postoperative patients with stage II-III CRC at two different hospitals as the training (n=310) and validation (n=139) cohorts. These findings were further validated in the independent cohort (Integration of GSE39582 and GSE17536, n=489). The AMC density was assessed using CD203c staining or the CIBERSORT method. The main analysis was recurrence-free survival (RFS) and overall survival (OS).

Results: As an independent factor, high AMC infiltration was associated with worse RFS/OS in the training (hazard ratio [HR]=3.437/3.014, all <0.001) and validation (HR=3.537/2.382, all <0.001) cohorts. We developed and validated an AMC-based nomogram for better stratification for postoperative recurrence in these two cohorts. The role of AMC density was further validated in the independent cohort. High AMC infiltration was associated with decreased RFS/OS after adjuvant chemotherapy (all <0.05). Approximately 74.2% of intramural CD203c AMCs expressed a high level of PD-L1. Multiple immunosuppressive pathways were enriched in high AMC infiltration tumors, including upregulation of the TNF-α/NF-κB and angiogenesis pathways and downregulation of the IFN-γ and IFN-α responses. AMC infiltration was reversely associated with CD8 T-cell infiltration (all <0.05).

Conclusion: High AMC infiltration is associated with worse survival outcomes in stages II-III CRC. AMC density may serve as a potential biomarker for survival benefit in patients receiving adjuvant chemotherapy. This AMC-based nomogram could provide better recurrence stratification. Immunosuppression in tumors with high AMC infiltration might contribute to promoting tumor progression.

Citing Articles

Mast cells: key players in digestive system tumors and their interactions with immune cells.

Shu F, Yu J, Liu Y, Wang F, Gou G, Wen M Cell Death Discov. 2025; 11(1):8.

PMID: 39814702 PMC: 11735678. DOI: 10.1038/s41420-024-02258-y.

CXCL6-CXCR2 axis-mediated PD-L2 mast cell accumulation shapes the immunosuppressive microenvironment in osteosarcoma.

Wang C, Lei Z, Zhang C, Hu X Heliyon. 2024; 10(14):e34290.

PMID: 39082021 PMC: 11284376. DOI: 10.1016/j.heliyon.2024.e34290.

Association between Atopic Dermatitis and Colorectal Cancer: TET2 as a Shared Gene Signature and Prognostic Biomarker.

Zhan Z, Huang Z, Zeng R, Luo Y, Xie Z, Chen Y J Cancer. 2024; 15(5):1414-1428.

PMID: 38356721 PMC: 10861813. DOI: 10.7150/jca.92238.

The regulatory role and mechanism of mast cells in tumor microenvironment.

Ligan C, Ma X, Zhao S, Zhao W Am J Cancer Res. 2024; 14(1):1-15.

PMID: 38323271 PMC: 10839313.

References

Wu X, Zou Y, He X, Yuan R, Chen Y, Lan N . Tumor-infiltrating mast cells in colorectal cancer as a poor prognostic factor. Int J Surg Pathol. 2012; 21(2):111-20. DOI: 10.1177/1066896912448836. View

Tan S, Fan Y, Luo H, Shen Z, Guo Y, Zhao L . Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol. 2005; 11(8):1210-4. PMC: 4250716. DOI: 10.3748/wjg.v11.i8.1210. View

Dudeck A, Dudeck J, Scholten J, Petzold A, Surianarayanan S, Kohler A . Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity. 2011; 34(6):973-84. DOI: 10.1016/j.immuni.2011.03.028. View

Galli S, Borregaard N, Wynn T . Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol. 2011; 12(11):1035-44. PMC: 3412172. DOI: 10.1038/ni.2109. View

Martinez-Camblor P, Pardo-Fernandez J . The Youden Index in the Generalized Receiver Operating Characteristic Curve Context. Int J Biostat. 2019; 15(1). DOI: 10.1515/ijb-2018-0060. View

Somasundaram R, Connelly T, Choi R, Choi H, Samarkina A, Li L . Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun. 2021; 12(1):346. PMC: 7804257. DOI: 10.1038/s41467-020-20600-7. View

Hu X, Li C, Chen J, Qin G . Confidence intervals for the Youden index and its optimal cut-off point in the presence of covariates. J Biopharm Stat. 2020; 31(3):251-272. DOI: 10.1080/10543406.2020.1832107. View

Mehdawi L, Osman J, Topi G, Sjolander A . High tumor mast cell density is associated with longer survival of colon cancer patients. Acta Oncol. 2016; 55(12):1434-1442. DOI: 10.1080/0284186X.2016.1198493. View

Nielsen H, Hansen U, Christensen I, Reimert C, Brunner N, Moesgaard F . Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol. 2000; 189(4):487-95. DOI: 10.1002/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-I. View

10.

Ogluszka M, Orzechowska M, Jedroszka D, Witas P, Bednarek A . Evaluate Cutpoints: Adaptable continuous data distribution system for determining survival in Kaplan-Meier estimator. Comput Methods Programs Biomed. 2019; 177:133-139. DOI: 10.1016/j.cmpb.2019.05.023. View

11.

Iwamoto T, Yuta A, Tabata T, Sugimoto H, Gabazza E, Hirai H . Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer. Biol Pharm Bull. 2012; 35(9):1487-95. DOI: 10.1248/bpb.b12-00150. View

12.

Elezoglu B, Tolunay S . The relationship between the stromal mast cell number, microvessel density, c-erbB-2 staining and survival and prognostic factors in colorectal carcinoma. Turk Patoloji Derg. 2012; 28(2):110-8. DOI: 10.5146/tjpath.2012.01109. View

13.

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

14.

Iveson T, Sobrero A, Yoshino T, Souglakos I, Ou F, Meyers J . Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. J Clin Oncol. 2021; 39(6):631-641. PMC: 8078416. DOI: 10.1200/JCO.20.01330. View

15.

Haller D, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E . Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011; 29(11):1465-71. DOI: 10.1200/JCO.2010.33.6297. View

16.

Acikalin M, Oner U, Topcu I, Yasar B, Kiper H, Colak E . Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. Dig Liver Dis. 2005; 37(3):162-9. DOI: 10.1016/j.dld.2004.09.028. View

17.

Khazaie K, Blatner N, Khan M, Gounari F, Gounaris E, Dennis K . The significant role of mast cells in cancer. Cancer Metastasis Rev. 2011; 30(1):45-60. DOI: 10.1007/s10555-011-9286-z. View

18.

Donate F, Raitano A, Morrison K, An Z, Capo L, Avina H . AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma. Clin Cancer Res. 2015; 22(8):1989-99. DOI: 10.1158/1078-0432.CCR-15-1542. View

19.

Mao Y, Feng Q, Zheng P, Yang L, Zhu D, Chang W . Low tumor infiltrating mast cell density confers prognostic benefit and reflects immunoactivation in colorectal cancer. Int J Cancer. 2018; 143(9):2271-2280. DOI: 10.1002/ijc.31613. View

20.

Harrell Jr F, Lee K, Mark D . Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15(4):361-87. DOI: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4. View